Woerner
07-21-2004, 07:48 AM
Phizer just released its second quarter earnings which show that the pharmaceutical's earnings remain unchanged by the recent Medicare drug benefit. Ananlysts report Phizer's drugs are performing well and are expected to increase income potential in the next few years.
"Our performance was strong despite these factors. Through restraint in spending, our 2004 bottom line will be unaffected. And going forward our expectations remain robust," Ms. Katen said."
"Pfizer's financial results in the second quarter reflect the Company's fundamental soundness and resilience in the face of dynamic market conditions," said Hank McKinnell, chairman and chief executive officer."
To read morw go to: http://biz.yahoo.com/prnews/040721/nyw090_1.html
"Our performance was strong despite these factors. Through restraint in spending, our 2004 bottom line will be unaffected. And going forward our expectations remain robust," Ms. Katen said."
"Pfizer's financial results in the second quarter reflect the Company's fundamental soundness and resilience in the face of dynamic market conditions," said Hank McKinnell, chairman and chief executive officer."
To read morw go to: http://biz.yahoo.com/prnews/040721/nyw090_1.html